Urine aquaporin-2: A promising marker of response to the arginine vasopressin type-2 antagonist, Tolvaptan in patients with congestive heart failure

International Journal of Molecular Sciences

Volumn 17, Issue 1, 2016, Pages

  Imamura, Teruhiko ^a   Kinugawa, Koichiro ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Chronic kidney disease; Congestion; Heart failure; Hyponatremia

Indexed keywords

AQUAPORIN 2; TOLVAPTAN; VASOPRESSIN; BENZAZEPINE DERIVATIVE; BIOLOGICAL MARKER; VASOPRESSIN RECEPTOR ANTAGONIST;

CONGESTIVE HEART FAILURE; DIABETES INSIPIDUS; ENZYME LINKED IMMUNOSORBENT ASSAY; GLOMERULUS FILTRATION RATE; HUMAN; HYPONATREMIA; KIDNEY FUNCTION; LIVER CIRRHOSIS; PREGNANCY; PROTEIN EXPRESSION; RADIOIMMUNOASSAY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; WESTERN BLOTTING; HEART FAILURE; URINE;

ANTIDIURETIC HORMONE RECEPTOR ANTAGONISTS; AQUAPORIN 2; BENZAZEPINES; BIOMARKERS; HEART FAILURE; HUMANS;

EID: 84954322574     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17010105     Document Type: Review

References (51)

1. Ishibashi, K.; Kondo, S.; Hara, S.; Morishita, Y. The evolutionary aspects of aquaporin family. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2011, 300, R566-R576. [CrossRef] [PubMed]
2. Park, E.J.; Kwon, T.H. A minireview on vasopressin-regulated aquaporin-2 in kidney collecting duct cells. Electrol. Blood Press. 2015, 13, 1-6. [CrossRef] [PubMed]
3. Ishikawa, S.E. Hyponatremia associated with heart failure: Pathological role of vasopressin-dependent impaired water excretion. J. Clin. Med. 2015, 4, 933-947. [CrossRef] [PubMed]
4. Kanno, K.; Sasaki, S.; Hirata, Y.; Ishikawa, S.; Fushimi, K.; Nakanishi, S.; Bichet, D.G.; Marumo, F. Urinary excretion of aquaporin-2 in patients with diabetes insipidus. N. Engl. J. Med. 1995, 332, 1540-1545. [CrossRef] [PubMed]
5. Ishikawa, S.; Saito, T.; Fukagawa, A.; Higashiyama, M.; Nakamura, T.; Kusaka, I.; Nagasaka, S.; Honda, K.; Saito, T. Close association of urinary excretion of aquaporin-2 with appropriate and inappropriate arginine vasopressin-dependent antidiuresis in hyponatremia in elderly subjects. J. Clin. Endocrinol. Metab. 2001, 86, 1665-1671. [CrossRef]
6. Robertson, G.L.; Mahr, E.A.; Athar, S.; Sinha, T. Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma. J. Clin. Investig. 1973, 52, 2340-2352. [CrossRef] [PubMed]
7. Rai, T.; Sekine, K.; Kanno, K.; Hata, K.; Miura, M.; Mizushima, A.; Marumo, F.; Sasaki, S. Urinary excretion of aquaporin-2 water channel protein in human and rat. J. Am. Soc. Nephrol. 1997, 8, 1357-1362. [PubMed]
8. Elliot, S.; Goldsmith, P.; Knepper, M.; Haughey, M.; Olson, B. Urinary excretion of aquaporin-2 in humans: A potential marker of collecting duct responsiveness to vasopressin. J. Am. Soc. Nephrol. 1996, 7, 403-409. [PubMed]
9. Umenishi, F.; Summer, S.N.; Cadnapaphornchai, M.; Schrier, R.W. Comparison of three methods to quantify urinary aquaporin-2 protein. Kidney Int. 2002, 62, 2288-2293. [CrossRef] [PubMed]
10. Sasaki, S.; Ohmoto, Y.; Mori, T.; Iwata, F.; Muraguchi, M. Daily variance of urinary excretion of AQP2 determined by sandwich elisa method. Clin. Exp. Nephrol. 2012, 16, 406-410. [CrossRef] [PubMed]
11. Buemi, M.; D'Anna, R.; di Pasquale, G.; Floccari, F.; Ruello, A.; Aloisi, C.; Leonardi, I.; Frisina, N.; Corica, F. Urinary excretion of aquaporin-2 water channel during pregnancy. Cell. Physiol. Biochem. 2001, 11, 203-208. [CrossRef] [PubMed]
12. Ivarsen, P.; Frokiaer, J.; Aagaard, N.K.; Hansen, E.F.; Bendtsen, F.; Nielsen, S.; Vilstrup, H. Increased urinary excretion of aquaporin 2 in patients with liver cirrhosis. Gut 2003, 52, 1194-1199. [CrossRef] [PubMed]
13. Funayama, H.; Nakamura, T.; Saito, T.; Yoshimura, A.; Saito, M.; Kawakami, M.; Ishikawa, S.E. Urinary excretion of aquaporin-2 water channel exaggerated dependent upon vasopressin in congestive heart failure. Kidney Int. 2004, 66, 1387-1392. [CrossRef] [PubMed]
14. Martin, P.Y.; Abraham, W.T.; Lieming, X.; Olson, B.R.; Oren, R.M.; Ohara, M.; Schrier, R.W. Selective V2-receptor vasopressin antagonism decreases urinary aquaporin-2 excretion in patients with chronic heart failure. J. Am. Soc. Nephrol. 1999, 10, 2165-2170. [PubMed]
15. Imamura, T.; Kinugawa, K.; Hatano, M.; Fujino, T.; Inaba, T.; Maki, H.; Kinoshita, O.; Nawata, K.; Kyo, S.; Ono, M.; et al. Low cardiac output stimulates vasopressin release in patients with stage D heart failure. Circ. J. 2014, 78, 2259-2267. [CrossRef] [PubMed]
16. Goldsmith, S.R.; Francis, G.S.; Cowley, A.W., Jr.; Levine, T.B.; Cohn, J.N. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J. Am. Coll. Cardiol. 1983, 1, 1385-1390. [CrossRef]
17. Szatalowicz, V.L.; Arnold, P.E.; Chaimovitz, C.; Bichet, D.; Berl, T.; Schrier, R.W. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N. Engl. J. Med. 1981, 305, 263-266. [CrossRef] [PubMed]
18. Pruszczynski, W.; Vahanian, A.; Ardaillou, R.; Acar, J. Role of antidiuretic hormone in impaired water excretion of patients with congestive heart failure. J. Clin. Endocrinol. Metab. 1984, 58, 599-605. [CrossRef] [PubMed]
19. Nakamura, T.; Funayama, H.; Yoshimura, A.; Tsuruya, Y.; Saito, M.; Kawakami, M.; Ishikawa, S.E. Possible vascular role of increased plasma arginine vasopressin in congestive heart failure. Int. J. Cardiol. 2006, 106, 191-195. [CrossRef] [PubMed]
20. Bettari, L.; Fiuzat, M.; Shaw, L.K.;Wojdyla, D.M.; Metra, M.; Felker, G.M.; O'Connor, C.M. Hyponatremia and long-term outcomes in chronic heart failure-An observational study from the duke databank for cardiovascular diseases. J. Card. Fail. 2012, 18, 74-81. [CrossRef] [PubMed]
21. Konishi, M.; Haraguchi, G.; Ohigashi, H.; Sasaoka, T.; Yoshikawa, S.; Inagaki, H.; Ashikaga, T.; Isobe, M. Progression of hyponatremia is associated with increased cardiac mortality in patients hospitalized for acute decompensated heart failure. J. Card. Fail. 2012, 18, 620-625. [CrossRef] [PubMed]
22. Sato, N.; Gheorghiade, M.; Kajimoto, K.; Munakata, R.; Minami, Y.; Mizuno, M.; Aokage, T.; Asai, K.; Sakata, Y.; Yumino, D.; et al. Hyponatremia and in-hospital mortality in patients admitted for heart failure (from the attend registry). Am. J. Cardiol. 2013, 111, 1019-1025. [CrossRef] [PubMed]
23. Gheorghiade, M.; Abraham, W.T.; Albert, N.M.; Gattis Stough, W.; Greenberg, B.H.; O'Connor, C.M.; She, L.; Yancy, C.W.; Young, J.; Fonarow, G.C.; et al. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: An analysis from the OPTIMIZE-HF registry. Eur. Heart J. 2007, 28, 980-988. [CrossRef] [PubMed]
24. Izumi, Y.; Miura, K.; Iwao, H. Therapeutic potential of vasopressin-receptor antagonists in heart failure. J. Pharmacol. Sci. 2014, 124, 1-6. [CrossRef] [PubMed]
25. Imamura, T.; Kinugawa, K.; Minatsuki, S.; Muraoka, H.; Kato, N.; Inaba, T.; Maki, H.; Hatano, M.; Yao, A.; Komuro, I. Tolvaptan can improve clinical course in responders. Int. Heart J. 2013, 54, 377-381. [CrossRef] [PubMed]
26. Imamura, T.; Kinugawa, K.; Shiga, T.; Kato, N.; Endo, M.; Inaba, T.; Maki, H.; Hatano, M.; Yao, A.; Hirata, Y.; et al. Correction of hyponatremia by tolvaptan before left ventricular assist device implantation. Int. Heart J. 2012, 53, 391-393. [CrossRef] [PubMed]
27. Imamura, T.; Kinugawa, K.; Kato, N.; Minatsuki, S.; Muraoka, H.; Inaba, T.; Maki, H.; Shiga, T.; Hatano, M.; Yao, A.; et al. Successful conversion from thiazide to tolvaptan in a patient with stage D heart failure and chronic kidney disease before heart transplantation. Int. Heart J. 2013, 54, 48-50. [CrossRef] [PubMed]
28. Kinugawa, K.; Imamura, T.; Komuro, I. Experience of a vasopressin receptor antagonist, tolvaptan, under the unique indication in Japanese heart failure patients. Clin. Pharmacol. Ther. 2013, 94, 449-451. [CrossRef] [PubMed]
29. Costello-Boerrigter, L.C.; Smith,W.B.; Boerrigter, G.; Ouyang, J.; Zimmer, C.A.; Orlandi, C.; Burnett, J.C., Jr. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am. J. Physiol. Ren. Physiol. 2006, 290, F273-F278. [CrossRef] [PubMed]
30. Schrier, R.W.; Gross, P.; Gheorghiade, M.; Berl, T.; Verbalis, J.G.; Czerwiec, F.S.; Orlandi, C. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N. Engl. J. Med. 2006, 355, 2099-2112. [CrossRef] [PubMed]
31. Udelson, J.E.; Orlandi, C.; Ouyang, J.; Krasa, H.; Zimmer, C.A.; Frivold, G.; Haught,W.H.; Meymandi, S.; Macarie, C.; Raef, D.; et al. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: An international, multicenter, randomized, placebo-controlled trial. J. Am. Coll. Cardiol. 2008, 52, 1540-1545. [CrossRef] [PubMed]
32. Berl, T.; Quittnat-Pelletier, F.; Verbalis, J.G.; Schrier, R.W.; Bichet, D.G.; Ouyang, J.; Czerwiec, F.S.; Investigators, S. Oral tolvaptan is safe and effective in chronic hyponatremia. J. Am. Soc. Nephrol. 2010, 21, 705-712. [CrossRef] [PubMed]
33. Kinugawa, K.; Sato, N.; Inomata, T.; Shimakawa, T.; Iwatake, N.; Mizuguchi, K. Efficacy and safety of tolvaptan in heart failure patients with volume overload. Circ. J. 2014, 78, 844-852. [CrossRef] [PubMed]
34. Matsuzaki, M.; Hori, M.; Izumi, T.; Fukunami, M.; Tolvaptan, I. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: A phase III, randomized, double-blind, placebo-controlled study (quest study). Cardiovasc. Drugs Ther. 2011, 25, S33-S45. [CrossRef] [PubMed]
35. Imamura, T.; Kinugawa, K. Mid-term administration of tolvaptan improves renal function accompanied by dose-reduction in furosemide in aquaporin-defined responders. Int. Heart J. 2015, 56, 686-687. [CrossRef] [PubMed]
36. Imamura, T.; Kinugawa, K.; Kato, N.; Minatsuki, S.; Muraoka, H.; Inaba, T.; Maki, H.; Shiga, T.; Hatano, M.; Hosoya, Y.; et al. A case with recovery of response to tolvaptan associated with remission of acute kidney injury and increased urine osmolality. Int. Heart J. 2013, 54, 115-118. [CrossRef] [PubMed]
37. Imamura, T.; Kinugawa, K.; Fujino, T.; Inaba, T.; Maki, H.; Hatano, M.; Yao, A.; Komuro, I. Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure. Circ. J. 2014, 78, 2240-2249. [CrossRef] [PubMed]
38. Konstam, M.A.; Gheorghiade, M.; Burnett, J.C., Jr.; Grinfeld, L.; Maggioni, A.P.; Swedberg, K.; Udelson, J.E.; Zannad, F.; Cook, T.; Ouyang, J.; et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The everest outcome trial. JAMA 2007, 297, 1319-1331. [CrossRef] [PubMed]
39. Hauptman, P.J.; Burnett, J.; Gheorghiade, M.; Grinfeld, L.; Konstam, M.A.; Kostic, D.; Krasa, H.B.; Maggioni, A.; Ouyang, J.; Swedberg, K.; et al. Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. J. Card. Fail. 2013, 19, 390-397. [CrossRef] [PubMed]
40. Imamura, T.; Kinugawa, K.; Shiga, T.; Kato, N.; Muraoka, H.; Minatsuki, S.; Inaba, T.; Maki, H.; Hatano, M.; Yao, A.; et al. Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients-Association between non-responders and chronic kidney disease. Circ. J. 2013, 77, 397-404. [CrossRef] [PubMed]
41. Imamura, T.; Kinugawa, K.; Minatsuki, S.; Muraoka, H.; Kato, N.; Inaba, T.; Maki, H.; Shiga, T.; Hatano, M.; Yao, A.; et al. Urine osmolality estimated using urine urea nitrogen, sodium and creatinine can effectively predict response to tolvaptan in decompensated heart failure patients. Circ. J. 2013, 77, 1208-1213. [CrossRef] [PubMed]
42. Toda, H.; Nakamura, K.; Nakahama, M.;Wada, T.;Watanabe, A.; Hashimoto, K.; Terasaka, R.; Tokioka, K.; Nishii, N.; Miyoshi, T.; et al. Clinical characteristics of responders to treatment with tolvaptan in patients with acute decompensated heart failure: Importance of preserved kidney size. J. Cardiol. 2015, 67, 177-183. [CrossRef] [PubMed]
43. Tanaka, A.; Katsuno, T.; Ozaki, T.; Sakata, F.; Kato, N.; Suzuki, Y.; Kosugi, T.; Kato, S.; Tsuboi, N.; Sato,W.; et al. The efficacy of tolvaptan as a diuretic for chronic kidney disease patients. Acta Cardiol. 2015, 70, 217-223. [PubMed]
44. Tominaga, N.; Kida, K.; Matsumoto, N.; Akashi, Y.J.; Miyake, F.; Kimura, K.; Shibagaki, Y. Safety of add-on tolvaptan in patients with furosemide-resistant congestive heart failure complicated by advanced chronic kidney disease: A sub-analysis of a pharmacokinetics/pharmacodynamics study. Clin. Nephrol. 2015, 84, 29-38. [CrossRef] [PubMed]
45. Iwatani, H.; Kawabata, H.; Sakaguchi, Y.; Yamamoto, R.; Hamano, T.; Rakugi, H.; Isaka, Y. Urine osmolarity predicts the body weight-reduction response to tolvaptan in chronic kidney disease patients: A retrospective, observational study. Nephron 2015, 130, 8-12. [CrossRef] [PubMed]
46. Imamura, T. Aquaporin-2-guided tolvaptan therapy in patients with congestive heart failure accompanied by chronic kidney disease. Int. Heart J. 2014, 55, 482-483. [CrossRef] [PubMed]
47. Jensen, J.M.; Mose, F.H.; Kulik, A.E.; Bech, J.N.; Fenton, R.A.; Pedersen, E.B. Abnormal urinary excretion of NKCC2 and AQP2 in response to hypertonic saline in chronic kidney disease: An intervention study in patients with chronic kidney disease and healthy controls. BMC Nephrol. 2014, 15, 101. [CrossRef] [PubMed]
48. Sato, E.; Nakamura, T.; Amaha, M.; Nomura, M.; Matsumura, D.; Yamagishi, H.; Ono, Y.; Ueda, Y. Effect of tolvaptan in patients with chronic kidney disease due to diabetic nephropathy with heart failure. Int. Heart J. 2014, 55, 533-538. [CrossRef] [PubMed]
49. Hirano, D.; Kakegawa, D.; Yamada, A.; Ito, A.; Miwa, S.; Ida, H. Tolvaptan in a pediatric patient with diuretic-resistant heart and kidney failure. Pediatr. Int. 2015, 57, 183-185. [CrossRef] [PubMed]
50. Otsuka, T.; Sakai, Y.; Ohno, D.; Murasawa, T.; Sato, N.; Tsuruoka, S. The effects of tolvaptan on patients with severe chronic kidney disease complicated by congestive heart failure. Clin. Exp. Nephrol. 2013, 17, 834-838. [CrossRef] [PubMed]
51. Imamura, T.; Kinugawa, K.; Komuro, I. Tolvaptan prolongs blockage of the vasopressin type II receptor over 24 hours in responders with stage D heart failure. Int. Heart J. 2016. in press. [CrossRef] [PubMed]